SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harry Ehrlich who wrote (1035)1/23/1998 2:59:00 PM
From: D.Right  Read Replies (2) of 2173
 
Dear Harry:

I would doubt that either the buyer or the seller knows anything that we don't know. If I have to take a guess I would say the weakness is related to the whole market condition. The key here is for AMLN to finish its enrollment of the European trials which would guarantee a new set of clinical III results about nine months from the completion. As they said it would be in the first quarter, we have a little more than two months to wait, the max.

Good day.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News